|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: GTF3C4 |
Gene summary for GTF3C4 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | GTF3C4 | Gene ID | 9329 |
| Gene name | general transcription factor IIIC subunit 4 | |
| Gene Alias | KAT12 | |
| Cytomap | 9q34.13 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | B3KNH2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9329 | GTF3C4 | HCC1_Meng | Human | Liver | HCC | 1.15e-15 | 1.09e-03 | 0.0246 |
| 9329 | GTF3C4 | HCC2_Meng | Human | Liver | HCC | 3.92e-08 | 6.02e-02 | 0.0107 |
| 9329 | GTF3C4 | HCC1 | Human | Liver | HCC | 1.20e-02 | 1.92e+00 | 0.5336 |
| 9329 | GTF3C4 | HCC2 | Human | Liver | HCC | 2.28e-12 | 1.92e+00 | 0.5341 |
| 9329 | GTF3C4 | S014 | Human | Liver | HCC | 1.97e-06 | 2.15e-01 | 0.2254 |
| 9329 | GTF3C4 | S015 | Human | Liver | HCC | 3.62e-09 | 3.93e-01 | 0.2375 |
| 9329 | GTF3C4 | S016 | Human | Liver | HCC | 1.13e-03 | 2.46e-01 | 0.2243 |
| 9329 | GTF3C4 | S027 | Human | Liver | HCC | 4.00e-04 | 5.30e-01 | 0.2446 |
| 9329 | GTF3C4 | S028 | Human | Liver | HCC | 5.84e-17 | 6.61e-01 | 0.2503 |
| 9329 | GTF3C4 | S029 | Human | Liver | HCC | 4.55e-14 | 5.36e-01 | 0.2581 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001657021 | Liver | HCC | histone modification | 283/7958 | 463/18723 | 2.68e-16 | 2.33e-14 | 283 |
| GO:00182052 | Liver | HCC | peptidyl-lysine modification | 230/7958 | 376/18723 | 1.51e-13 | 8.32e-12 | 230 |
| GO:00064732 | Liver | HCC | protein acetylation | 135/7958 | 201/18723 | 1.20e-12 | 5.92e-11 | 135 |
| GO:00435432 | Liver | HCC | protein acylation | 157/7958 | 243/18723 | 2.40e-12 | 1.12e-10 | 157 |
| GO:00183942 | Liver | HCC | peptidyl-lysine acetylation | 116/7958 | 169/18723 | 5.11e-12 | 2.23e-10 | 116 |
| GO:00064752 | Liver | HCC | internal protein amino acid acetylation | 107/7958 | 160/18723 | 3.77e-10 | 1.23e-08 | 107 |
| GO:00183932 | Liver | HCC | internal peptidyl-lysine acetylation | 105/7958 | 158/18723 | 9.48e-10 | 2.90e-08 | 105 |
| GO:00165732 | Liver | HCC | histone acetylation | 101/7958 | 152/18723 | 1.99e-09 | 5.63e-08 | 101 |
| GO:0006352 | Liver | HCC | DNA-templated transcription, initiation | 78/7958 | 130/18723 | 4.19e-05 | 4.11e-04 | 78 |
| GO:0009303 | Liver | HCC | rRNA transcription | 25/7958 | 34/18723 | 2.42e-04 | 1.81e-03 | 25 |
| GO:0006383 | Liver | HCC | transcription by RNA polymerase III | 31/7958 | 46/18723 | 5.67e-04 | 3.61e-03 | 31 |
| GO:0098781 | Liver | HCC | ncRNA transcription | 33/7958 | 56/18723 | 9.64e-03 | 3.63e-02 | 33 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| GTF3C4 | SNV | Missense_Mutation | c.1543N>G | p.Leu515Val | p.L515V | Q9UKN8 | protein_coding | tolerated(0.1) | possibly_damaging(0.714) | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| GTF3C4 | SNV | Missense_Mutation | c.1612G>A | p.Asp538Asn | p.D538N | Q9UKN8 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-A8-A0A9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD | |
| GTF3C4 | SNV | Missense_Mutation | novel | c.1784N>T | p.Ala595Val | p.A595V | Q9UKN8 | protein_coding | tolerated_low_confidence(0.54) | benign(0) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| GTF3C4 | SNV | Missense_Mutation | novel | c.2466N>A | p.Phe822Leu | p.F822L | Q9UKN8 | protein_coding | tolerated(0.95) | benign(0.177) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| GTF3C4 | SNV | Missense_Mutation | novel | c.779N>G | p.Gln260Arg | p.Q260R | Q9UKN8 | protein_coding | tolerated(0.44) | benign(0.23) | TCGA-E9-A1N9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| GTF3C4 | SNV | Missense_Mutation | novel | c.2219A>G | p.Lys740Arg | p.K740R | Q9UKN8 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.998) | TCGA-OL-A5RU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | CR |
| GTF3C4 | SNV | Missense_Mutation | novel | c.382G>C | p.Glu128Gln | p.E128Q | Q9UKN8 | protein_coding | tolerated(0.19) | benign(0.043) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
| GTF3C4 | insertion | In_Frame_Ins | novel | c.1172_1173insACA | p.Val391_Val392insGln | p.V391_V392insQ | Q9UKN8 | protein_coding | TCGA-A2-A0D4-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
| GTF3C4 | insertion | Nonsense_Mutation | novel | c.1174_1175insTACACCAGCTGGTCTCCCATGGGTTGCGATGCTAA | p.Ala393HisfsTer11 | p.A393Hfs*11 | Q9UKN8 | protein_coding | TCGA-A2-A0D4-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
| GTF3C4 | insertion | Nonsense_Mutation | novel | c.2010_2011insTCTCCATGACTGCAGACAAACAGAAT | p.Glu671SerfsTer3 | p.E671Sfs*3 | Q9UKN8 | protein_coding | TCGA-A8-A06P-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unspecific | SD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |